Exposing a β-Lactamase “Twist”: the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase

ABSTRACT Around the world, Burkholderia spp. are emerging as pathogens highly resistant to β-lactam antibiotics, especially ceftazidime. Clinical variants of Burkholderia pseudomallei possessing the class A β-lactamase PenI with substitutions at positions C69 and P167 are known to demonstrate ceftazidime resistance. However, the biochemical basis for ceftazidime resistance in class A β-lactamases in B. pseudomallei is largely undefined. Here, we performed site saturation mutagenesis of the C69 position and investigated the kinetic properties of the C69F variant of PenI from B. pseudomallei that results in a high level of ceftazidime resistance (2 to 64 mg/liter) when expressed in Escherichia coli. Surprisingly, quantitative immunoblotting showed that the steady-state protein levels of the C69F variant β-lactamase were ∼4-fold lower than those of wild-type PenI (0.76 fg of protein/cell versus 4.1 fg of protein/cell, respectively). However, growth in the presence of ceftazidime increases the relative amount of the C69F variant to greater than wild-type PenI levels. The C69F variant exhibits a branched kinetic mechanism for ceftazidime hydrolysis, suggesting there are two different conformations of the enzyme. When incubated with an anti-PenI antibody, one conformation of the C69F variant rapidly hydrolyzes ceftazidime and most likely contributes to the higher levels of ceftazidime resistance observed in cell-based assays. Molecular dynamics simulations suggest that the electrostatic characteristics of the oxyanion hole are altered in the C69F variant. When ceftazidime was positioned in the active site, the C69F variant is predicted to form a greater number of hydrogen-bonding interactions than PenI with ceftazidime. In conclusion, we propose “a new twist” for enhanced ceftazidime resistance mediated by the C69F variant of the PenI β-lactamase based on conformational changes in the C69F variant. Our findings explain the biochemical basis of ceftazidime resistance in B. pseudomallei, a pathogen of considerable importance, and suggest that the full repertoire of conformational states of a β-lactamase profoundly affects β-lactam resistance.

[1]  Jordan P Volpato,et al.  Combinatorial active‐site variants confer sustained clavulanate resistance in BlaC β‐lactamase from Mycobacterium tuberculosis , 2015, Protein science : a publication of the Protein Society.

[2]  Kathryn M Hart,et al.  Discovery of multiple hidden allosteric sites by combining Markov state models and experiments , 2015, Proceedings of the National Academy of Sciences.

[3]  B. Currie Melioidosis: Evolving Concepts in Epidemiology, Pathogenesis, and Treatment , 2015, Seminars in Respiratory and Critical Care Medicine.

[4]  Paul R. Carey,et al.  Following Drug Uptake and Reactions inside Escherichia coli Cells by Raman Microspectroscopy , 2014, Biochemistry.

[5]  R. Bonomo,et al.  Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae. , 2013, Diagnostic microbiology and infectious disease.

[6]  R. Bonomo,et al.  Insights into β-Lactamases from Burkholderia Species, Two Phylogenetically Related yet Distinct Resistance Determinants* , 2013, The Journal of Biological Chemistry.

[7]  R. Bonomo,et al.  Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. , 2013, Journal of medicinal chemistry.

[8]  S. Mobashery,et al.  Bacterial cell‐wall recycling , 2013, Annals of the New York Academy of Sciences.

[9]  H. Schweizer Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. , 2012, Future microbiology.

[10]  P. Keim,et al.  Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection , 2012, Infection and drug resistance.

[11]  R. Bonomo,et al.  Exploring the Role of a Conserved Class A Residue in the Ω-Loop of KPC-2 β-Lactamase , 2012, The Journal of Biological Chemistry.

[12]  D. Ehmann,et al.  Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor , 2012, Proceedings of the National Academy of Sciences.

[13]  Robert A. Bonomo,et al.  Understanding the Molecular Determinants of Substrate and Inhibitor Specificities in the Carbapenemase KPC-2: Exploring the Roles of Arg220 and Glu276 , 2012, Antimicrobial Agents and Chemotherapy.

[14]  D. Engelthaler,et al.  Characterization of Ceftazidime Resistance Mechanisms in Clinical Isolates of Burkholderia pseudomallei from Australia , 2012, PloS one.

[15]  H. Schweizer,et al.  Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei , 2011, Proceedings of the National Academy of Sciences.

[16]  R. Bonomo,et al.  Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei , 2011, Front. Microbio..

[17]  R. Bonomo,et al.  Elucidating the role of Trp105 in the KPC‐2 β‐lactamase , 2010, Protein science : a publication of the Protein Society.

[18]  R. Bonomo,et al.  Inhibitor Resistance in the KPC-2 β-Lactamase, a Preeminent Property of This Class A β-Lactamase , 2009, Antimicrobial Agents and Chemotherapy.

[19]  S. Puthucheary,et al.  Variations in Ceftazidime and Amoxicillin-Clavulanate Susceptibilities within a Clonal Infection of Burkholderia pseudomallei , 2009, Journal of Clinical Microbiology.

[20]  P. Nordmann,et al.  Naturally Occurring Class A ß-Lactamases from the Burkholderia cepacia Complex , 2008, Antimicrobial Agents and Chemotherapy.

[21]  M. Aschi,et al.  Natural D240G Toho-1 mutant conferring resistance to ceftazidime: biochemical characterization of CTX-M-43. , 2008, The Journal of antimicrobial chemotherapy.

[22]  A. Cheng,et al.  A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  R. Bonomo,et al.  Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates. , 2006, Biochemistry.

[24]  M. Page,et al.  The kinetics of non-stoichiometric bursts of-lactam hydrolysis catalysed by class C f-lactamases , 2005 .

[25]  Richard A. Moore,et al.  Burkholderia pseudomallei Class A β-Lactamase Mutations That Confer Selective Resistance against Ceftazidime or Clavulanic Acid Inhibition , 2003, Antimicrobial Agents and Chemotherapy.

[26]  R. Bonomo,et al.  Unexpected Advanced Generation Cephalosporinase Activity of the M69F Variant of SHV β-Lactamase* 210 , 2002, The Journal of Biological Chemistry.

[27]  V. Wuthiekanun,et al.  Cloning of the class D beta-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. , 2002, The Journal of antimicrobial chemotherapy.

[28]  Brian K Shoichet,et al.  The Structural Bases of Antibiotic Resistance in the Clinically Derived Mutant β-Lactamases TEM-30, TEM-32, and TEM-34* , 2002, The Journal of Biological Chemistry.

[29]  Yun Zhang,et al.  Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM beta-lactamase from Escherichia coli. , 2002, Journal of the American Chemical Society.

[30]  S. Madec,et al.  Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors. , 2002, FEMS microbiology letters.

[31]  P. Woo,et al.  Cloning and Expression of Class A β-Lactamase Gene blaABPS in Burkholderia pseudomallei , 2002, Antimicrobial Agents and Chemotherapy.

[32]  K. Yuen,et al.  Cloning and expression of class A beta-lactamase gene blaA(BPS) in Burkholderia pseudomallei. , 2002, Antimicrobial agents and chemotherapy.

[33]  M. Samuel,et al.  Interventions for treating melioidosis. , 2002, The Cochrane database of systematic reviews.

[34]  G. Paul,et al.  Catalytic and structural properties of IRT-21 beta-lactamase (TEM-77) from a co-amoxiclav-resistant Proteus mirabilis isolate. , 2001, FEMS microbiology letters.

[35]  I. Massova,et al.  Effects on Substrate Profile by Mutational Substitutions at Positions 164 and 179 of the Class A TEMpUC19 β-Lactamase from Escherichia coli* , 1999, The Journal of Biological Chemistry.

[36]  R. Bonomo,et al.  Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme. , 1998, The Biochemical journal.

[37]  R. Labia,et al.  Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling. , 1998, Biochimica et biophysica acta.

[38]  R. Labia,et al.  Clinical inhibitor-resistant mutants of the β-lactamase TEM-1 at amino-acid position 69 , 1998 .

[39]  R. Bonomo,et al.  Complementary roles of mutations at positions 69 and 242 in a class A beta-lactamase. , 1995, Biochimica et Biophysica Acta.

[40]  M. Page,et al.  The kinetics of non-stoichiometric bursts of beta-lactam hydrolysis catalysed by class C beta-lactamases. , 1993, Biochemical Journal.

[41]  J. Samama,et al.  Site-directed mutagenesis at the active site of Escherichia coli TEM-1 beta-lactamase. Suicide inhibitor-resistant mutants reveal the role of arginine 244 and methionine 69 in catalysis. , 1992, The Journal of biological chemistry.

[42]  S. Waley The kinetics of substrate-induced inactivation. , 1991, The Biochemical journal.

[43]  D. Dance,et al.  Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase , 1991, Antimicrobial Agents and Chemotherapy.

[44]  D. Dance,et al.  Pseudomonas pseudomallei Resistance tor-Lactam Antibiotics Due toAlterations intheChromosomally Encoded1-Lactamase , 1991 .

[45]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[46]  Pratt Rf,et al.  Mechanism of inhibition of the PC1 .beta.-lactamase of Staphylococcus aureus by cephalosporins: importance of the 3'-leaving group , 1985 .

[47]  R. Pratt,et al.  Mechanism of inhibition of the PC1 beta-lactamase of Staphylococcus aureus by cephalosporins: importance of the 3'-leaving group. , 1985, Biochemistry.

[48]  A. Samuni,et al.  Acquisition of substrate-specific parameters during the catalytic reaction of penicillinase. , 1976, Proceedings of the National Academy of Sciences of the United States of America.